Renshentang Alleviates Atherosclerosis in Mice by Targeting TRPV1 to Regulate Foam Cell Cholesterol Metabolism
10.13422/j.cnki.syfjx.20250903
- VernacularTitle:人参汤通过TRPV1调控泡沫细胞胆固醇代谢对AS小鼠的影响
- Author:
Yulu YUAN
1
;
Ce CHU
1
;
Xuguang TAO
1
;
Zhen YANG
2
;
Xiangyun CHEN
2
;
Zhanzhan HE
3
;
Yongqi XU
1
;
Yuxin ZHANG
1
;
Peizhang ZHAO
4
;
Wanping CHEN
1
;
Hongxia ZHAO
1
;
Wenlai WANG
1
Author Information
1. Institute of Basic Theory for Traditional Chinese Medicine， China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Beijing University of Chinese Medicine，Beijing 100029，China
3. Lanxi Traditional Chinese Medicine Hospital，Lanxi 321100，China
4. West China School of Medicine，Sichuan University，Chengdu 610041，China
- Publication Type:Journal Article
- Keywords:
Renshentang;
atherosclerosis;
cholesterol metabolism;
transient receptor potential vanilloid1 （TRPV1）
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(17):11-19
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the effects of Renshentang on atherosclerosis （AS） in mice based on the role of transient receptor potential vanilloid1 （TRPV1） in regulating cholesterol metabolism in foam cells. MethodsNine SPF-grade 8-week-old C57BL/6J mice were set as a normal group， and 60 ApoE-/- mice were randomized into model， positive drug （simvastatin， 0.02 g·kg-1·d-1）， and low-， medium-， and high-dose （1.77， 3.54， 7.08 g·kg-1·d-1， respectively） Renshentang groups （n=12） according to body weight. The normal group was fed with a normal diet， and the other groups were fed with a high-fat diet and given corresponding drugs by oral gavage for the modeling of AS. The mice were administrated with corresponding drugs once a day for 12 weeks. After the last administration and fasting for 12 h， the aorta was collected. Plaque conditions， pathological changes， levels of total cholesterol （TC）， triglcerides （TG）， low-density lipoprotein-cholesterol （LDL-C）， and high-density lipoprotein-cholesterol （HDL-C）， and the expression of TRPV1， liver X receptor （LXR）， inducible degrader of the low-density lipoprotein receptor （IDOL）， and low-density lipoprotein receptor （LDLR） in the aortic tissue were observed and detected by gross oil red O staining， HE staining， Western blot， immunohistochemistry， and real-time PCR. ResultsCompared with the normal group， the model group presented obvious plaque deposition in the aorta， raised levels of TC， TG， and LDL-C in the serum （P<0.01）， up-regulated expression level of LDLR in the aorta （P<0.01）， lowered level of HDL-C in the serum， and down-regulated expression levels of TRPV1， LXR， and IDOL in the aorta （P<0.05， P<0.01）. Compared with the model group， the positive drug and Renshentang at different doses alleviated AS， elevated the levels of HDL-C， TRPV1， LXR， and IDOL （P<0.05， P<0.01）， while lowering the levels of TC， TG， LDL-C， and LDLR （P<0.05， P<0.01）. ConclusionRenshentang has a lipid-lowering effect on AS mice. It can effectively reduce lipid deposition， lipid levels， and plaque area of AS mice by activating TRPV1 expression and regulating the LXR/IDOL/LDLR pathway.
